Neuronetics second quarter 2026 revenue of $41.6M beat estimates while reaching positive adjusted EBITDA

Neuronetics reported second quarter 2026 revenue of $41.6 million, significantly exceeding analyst estimates. While consolidated revenue grew 9.1% year-over-year, the performance was primarily driven by the Greenbrook clinic segment, which saw 16.8% growth, offsetting a 2.7% decline in NeuroStar technology revenue. The company achieved a financial milestone by reaching positive adjusted EBITDA for the first time in its history.

Key Highlights

• Adjusted EBITDA reached $0.3 million, a significant improvement from the $5.6 million loss recorded in the second quarter of 2025.
• Gross margins expanded to 51.1% from 46.6%, driven by a new go-to-market strategy and improved revenue cycle management within the clinic network.
• The company narrowed its full-year 2026 revenue guidance to $160 million–$164 million while raising its gross margin outlook to 48%–50%.